Stock Market Reviews

ALEC (Alector, Inc.) News

Get the latest news, insights, and market updates on ALEC (Alector, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer
  SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that Neil Berkley, who has served as Alector’s Chief Business Officer (CBO) since March 2024, and CBO and Interim Chief Financial Officer (CFO) since June 2025, has been appointed CFO, effective December 10, 2025. Mr. Berkley will continue to serve as CBO.
  Dec 12, 2025 - $ALEC
• How the Narrative Surrounding Alector Has Changed After the Latozinemab Trial Failure
  Alector’s latest narrative update leaves its fair value estimate steady at $2.05 per share, even as a slightly higher discount rate and still sharply negative revenue growth outlook underscore rising perceived risk. These tweaks largely reflect the fallout from the failed Phase 3 INFRONT 3 trial and the shift toward earlier stage assets, which pushes value creation further into the future while keeping intrinsic value effectively capped for now. Stay tuned to see how you can monitor these...
  Dec 5, 2025 - $ALEC
• Alector to Participate in the Bank of America CNS Therapeutics Conference
  SOUTH SAN FRANCISCO, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in a fireside chat at the Bank of America CNS Therapeutics Conference, being held virtually on Monday, December 8, 2025, at 2:25 pm ET. A webcast of the fireside chat will be available on the “Events & Presentations” page w
  Dec 1, 2025 - $ALEC
• How Analysts See Alector’s Story Shifting After the Latest Clinical Setback
  Alector's consensus analyst price target has recently dropped from $2.20 to $2.05 per share, signaling reduced confidence in the company's near-term outlook. This adjustment comes after the release of negative late-stage clinical data, which has prompted analysts to reassess both the risks and opportunities for the stock. Read on to find out how you can stay ahead of further shifts in Alector's evolving narrative. Analyst Price Targets don't always capture the full story. Head over to our...
  Nov 21, 2025 - $ALEC
• Alector Stock Plummets 63% in a Month: Here's What You Need to Know
  ALEC stock plunges after its dementia candidate fails to slow disease progression in a late-stage study, prompting job cuts and a strategic pipeline shift.
  Nov 18, 2025 - $ALEC
• How the Narrative Around Alector Is Evolving After the Latest Clinical Setback
  Alector's stock narrative has shifted following the disappointing results of its INFRONT-3 trial. This has prompted analysts to reassess the company's valuation and outlook. The fair value target remains steady at $2.20 per share, but the discount rate has risen slightly, and revenue growth projections have taken a sharp downturn. Investors interested in how these changes impact Alector's future should stay tuned for ongoing updates on the evolving narrative surrounding the stock. Analyst...
  Nov 7, 2025 - $ALEC
• Alector (ALEC) Reports Q3 Loss, Beats Revenue Estimates
  Alector (ALEC) delivered earnings and revenue surprises of +19.05% and +24.19%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 6, 2025 - $ALEC
• Alector: Q3 Earnings Snapshot
  SOUTH SAN FRANCISCO, Calif. AP) — Alector Inc. ALEC) on Thursday reported a loss of $34.7 million in its third quarter.
  Nov 6, 2025 - $ALEC
• Alector Reports Third Quarter 2025 Financial Results and Provides Business Update
  Selected lead candidates AL137 for the company’s Alector Brain Carrier (ABC)-enabled anti-amyloid beta antibody in Alzheimer's disease, and AL050 for its ABC-enabled GCase enzyme replacement therapy in Parkinson’s disease; both advancing toward IND-enabling studies Advancing ABC-enabled Tau, Alpha Synuclein and NLRP3 siRNA programs targeting peripheral delivery of novel therapies for neurodegenerative disorders Independent interim analysis for the PROGRESS-AD Phase 2 clinical trial of nivisnebar
  Nov 6, 2025 - $ALEC
• Alector Announces Topline Results from Phase 3 INFRONT-3 Clinical Trial Evaluating Latozinemab
  Alector Inc. (NASDAQ:ALEC) is one of the best stocks under $3 to invest in. On October 21, Alector announced the topline results from the Phase 3 INFRONT-3 clinical trial evaluating latozinemab (AL001) in individuals with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN). The 96-week, double-blind INFRONT-3 trial, developed in collaboration with GSK, did […]
  Oct 31, 2025 - $ALEC